Omnicell, Inc. (OMCL) Financial Ratios
26 years of historical data (2000–2025) · Healthcare · Medical - Healthcare Information Services
EV/EBITDA
↓
21.25
↓-29% vs avg
5yr avg: 29.98
30Y Low10.8·High50.7
P/FCF
↓
20.44
↓-55% vs avg
5yr avg: 45.68
30Y Low9.5·High135.8
P/B Ratio
↓
1.47
↓-49% vs avg
5yr avg: 2.88
30Y Low1.4·High11.8
ROE
↓
0.2%
↑-89% vs avg
5yr avg: 1.5%
30Y Low-28%·High29%
Debt/EBITDA
↓
2.43
↓-50% vs avg
5yr avg: 4.84
30Y Low0.0·High8.1
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
OMCL Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Omnicell, Inc. trades at 881.5x earnings, 105% above its 5-year average of 429.8x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 3885%. On a free-cash-flow basis, the stock trades at 20.4x P/FCF, 55% below the 5-year average of 45.7x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.8B | $2.1B | $2.1B | $1.7B | $2.3B | $8.7B | $5.3B | $3.5B | $2.5B | $1.9B | $1.2B |
| Enterprise Value | $1.8B | $2.1B | $2.1B | $1.8B | $2.6B | $8.8B | $5.3B | $3.5B | $2.6B | $2.1B | $1.4B |
| P/E Ratio → | 881.49 | 1022.57 | 164.89 | — | 420.17 | 111.38 | 162.19 | 57.15 | 65.85 | 61.39 | 130.38 |
| P/S Ratio | 1.50 | 1.77 | 1.85 | 1.48 | 1.79 | 7.64 | 5.88 | 3.91 | 3.15 | 2.62 | 1.80 |
| P/B Ratio | 1.47 | 1.70 | 1.66 | 1.43 | 2.05 | 7.54 | 5.43 | 4.15 | 3.65 | 3.63 | 2.90 |
| P/FCF | 20.44 | 24.17 | 13.61 | 12.19 | 135.78 | 42.65 | 40.08 | 42.11 | 50.09 | — | 66.57 |
| P/OCF | 13.95 | 16.50 | 10.97 | 9.39 | 29.75 | 37.32 | 28.25 | 24.20 | 23.89 | 75.60 | 26.07 |
P/E links to full P/E history page with 30-year chart
OMCL EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Omnicell, Inc.'s enterprise value stands at 21.2x EBITDA, 29% below its 5-year average of 30.0x. The Healthcare sector median is 14.2x, placing the stock at a 49% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.78 | 1.86 | 1.61 | 2.01 | 7.81 | 5.93 | 3.89 | 3.24 | 2.87 | 2.09 |
| EV / EBITDA | 21.25 | 25.11 | 23.01 | 24.24 | 26.85 | 50.69 | 49.41 | 24.52 | 26.66 | 35.89 | 22.35 |
| EV / EBIT | 345.68 | 120.53 | 6150.20 | — | — | 98.79 | 148.97 | 44.58 | 57.49 | 184.41 | 67.71 |
| EV / FCF | — | 24.26 | 13.70 | 13.23 | 152.58 | 43.59 | 40.40 | 41.91 | 51.46 | — | 77.21 |
OMCL Profitability
Margins and return-on-capital ratios measuring operating efficiency
Omnicell, Inc. earns an operating margin of 0.4%. Operating margins have expanded from -1.7% to 0.4% over the past 3 years, signaling improving operational efficiency. ROE of 0.2% is modest. ROIC of 0.3% represents below-average returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 42.5% | 42.5% | 42.3% | 43.6% | 45.4% | 49.0% | 46.3% | 48.7% | 47.3% | 45.0% | 45.3% |
| Operating Margin | 0.4% | 0.4% | 0.0% | -1.7% | -0.2% | 7.9% | 4.0% | 8.7% | 5.6% | 0.8% | 0.9% |
| Net Profit Margin | 0.2% | 0.2% | 1.1% | -1.8% | 0.4% | 6.9% | 3.6% | 6.8% | 4.8% | 2.9% | 0.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 0.2% | 0.2% | 1.0% | -1.8% | 0.5% | 7.4% | 3.6% | 8.0% | 6.3% | 4.3% | 0.1% |
| ROA | 0.1% | 0.1% | 0.6% | -0.9% | 0.3% | 3.9% | 2.1% | 5.3% | 3.7% | 2.2% | 0.1% |
| ROIC | 0.3% | 0.3% | 0.0% | -1.1% | -0.1% | 5.7% | 2.9% | 7.5% | 4.6% | 0.7% | 1.0% |
| ROCE | 0.3% | 0.3% | 0.0% | -1.1% | -0.2% | 6.4% | 2.8% | 8.3% | 5.4% | 0.8% | 1.1% |
OMCL Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Omnicell, Inc. carries a Debt/EBITDA ratio of 2.4x, which is manageable (24% below the sector average of 3.2x). Net debt stands at $8M ($204M total debt minus $197M cash). Interest coverage of just 2.8x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.17 | 0.17 | 0.31 | 0.52 | 0.55 | 0.47 | 0.55 | 0.13 | 0.20 | 0.41 | 0.59 |
| Debt / EBITDA | 2.43 | 2.43 | 4.25 | 8.06 | 6.37 | 3.10 | 4.93 | 0.78 | 1.41 | 3.67 | 3.92 |
| Net Debt / Equity | — | 0.01 | 0.01 | 0.12 | 0.25 | 0.17 | 0.04 | -0.02 | 0.10 | 0.34 | 0.46 |
| Net Debt / EBITDA | 0.09 | 0.09 | 0.15 | 1.92 | 2.96 | 1.10 | 0.40 | -0.12 | 0.71 | 3.10 | 3.08 |
| Debt / FCF | — | 0.09 | 0.09 | 1.05 | 16.81 | 0.95 | 0.32 | -0.20 | 1.38 | — | 10.64 |
| Interest Coverage | 2.84 | 2.84 | 0.07 | — | -17.87 | 4.00 | 16.94 | 13.50 | — | — | — |
OMCL Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.43x means Omnicell, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 2.52x to 1.43x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.43 | 1.43 | 1.37 | 2.52 | 2.06 | 0.89 | 3.00 | 2.04 | 1.94 | 1.73 | 1.74 |
| Quick Ratio | 1.22 | 1.22 | 1.22 | 2.22 | 1.71 | 0.75 | 2.65 | 1.58 | 1.45 | 1.28 | 1.36 |
| Cash Ratio | 0.41 | 0.41 | 0.64 | 1.27 | 0.80 | 0.41 | 1.79 | 0.58 | 0.33 | 0.15 | 0.30 |
| Asset Turnover | — | 0.60 | 0.52 | 0.52 | 0.59 | 0.53 | 0.49 | 0.72 | 0.73 | 0.73 | 0.74 |
| Inventory Turnover | 6.75 | 6.75 | 7.23 | 5.88 | 4.79 | 4.81 | 4.97 | 4.26 | 4.11 | 4.10 | 5.47 |
| Days Sales Outstanding | — | 66.80 | 84.14 | 83.97 | 84.34 | 77.67 | 77.78 | 88.85 | 90.98 | 101.33 | 79.21 |
OMCL Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Omnicell, Inc. returns 4.4% to shareholders annually primarily through share buybacks. The earnings yield of 0.1% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 0.1% | 0.1% | 0.6% | — | 0.2% | 0.9% | 0.6% | 1.7% | 1.5% | 1.6% | 0.8% |
| FCF Yield | 4.9% | 4.1% | 7.3% | 8.2% | 0.7% | 2.3% | 2.5% | 2.4% | 2.0% | — | 1.5% |
| Buyback Yield | 4.4% | 3.7% | 0.0% | 0.0% | 2.3% | 0.2% | 1.0% | 0.0% | 0.0% | 0.0% | 0.3% |
| Total Shareholder Yield | 4.4% | 3.7% | 0.0% | 0.0% | 2.3% | 0.2% | 1.0% | 0.0% | 0.0% | 0.0% | 0.3% |
| Shares Outstanding | — | $46M | $46M | $45M | $46M | $48M | $44M | $43M | $41M | $39M | $37M |
Peer Comparison
Compare OMCL with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 OMCLYou | $2B | 881.5 | 21.2 | 20.4 | 42.5% | 0.4% | 0.2% | 0.3% | 2.4 |
 BDX | $52B | 24.7 | 14.0 | 19.5 | 45.4% | 11.8% | 6.5% | 4.3% | 3.8 |
 HSIC | $9B | 24.4 | 11.9 | 16.0 | 29.1% | 5.7% | 8.3% | 7.1% | 3.4 |
 MCK | $90B | 19.6 | 13.2 | 15.8 | 3.6% | 1.6% | — | 254.1% | 1.2 |
 CAH | $52B | 34.4 | 18.8 | 28.2 | 3.7% | 1.0% | — | 3378.7% | 3.0 |
 VEEV | $25B | 28.2 | 19.7 | 18.0 | 75.5% | 28.7% | 13.9% | 12.9% | 0.1 |
 HCAT | $129M | -0.7 | 17.3 | — | 33.5% | -11.6% | -58.3% | -6.1% | 11.9 |
 AMZN | $2.6T | 34.1 | 18.5 | 341.6 | 50.3% | 11.2% | 22.3% | 14.7% | 1.0 |
 MSFT | $2.8T | 27.8 | 17.8 | 39.4 | 68.8% | 45.6% | 33.3% | 24.9% | 0.7 |
 ISRG | $144B | 51.7 | 39.0 | 58.0 | 66.0% | 29.3% | 16.6% | 15.0% | 0.1 |
 BAX | $10B | -11.4 | 27.2 | 31.8 | 30.1% | -2.7% | -14.6% | -1.4% | 14.9 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 26 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
OMCL — Frequently Asked Questions
Quick answers to the most common questions about buying OMCL stock.
What is Omnicell, Inc.'s P/E ratio?
Omnicell, Inc.'s current P/E ratio is 881.5x. The historical average is 68.9x. This places it at the 100th percentile of its historical range.
What is Omnicell, Inc.'s EV/EBITDA?
Omnicell, Inc.'s current EV/EBITDA is 21.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 25.1x.
What is Omnicell, Inc.'s ROE?
Omnicell, Inc.'s return on equity (ROE) is 0.2%. The historical average is 5.0%.
Is OMCL stock overvalued?
Based on historical data, Omnicell, Inc. is trading at a P/E of 881.5x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Omnicell, Inc.'s profit margins?
Omnicell, Inc. has 42.5% gross margin and 0.4% operating margin.
How much debt does Omnicell, Inc. have?
Omnicell, Inc.'s Debt/EBITDA ratio is 2.4x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.